Isha Jain and her team developed a drug that mimics the effects of breathing low oxygen, which could be life-saving for people with mitochondrial diseases who rarely survive past childhood. In mice with Leigh Syndrome—the most common childhood mitochondrial disease—the drug extended lifespan three-fold and reversed symptoms, even when given during late stages of disease. The new drug shows the promise of gas-based therapies for mitochondrial diseases and other common brain and cardiovascular conditions for which low oxygen has been shown to be beneficial. In this video, Jain and research associate Skyler Blume explain the science behind their discovery and the impact it could have for mitochondrial diseases.
关于我们
Gladstone's mission is to drive a new era of discovery in disease-oriented science and to mentor tomorrow’s leaders in an inspiring and diverse environment. Although Gladstone shares traits with other top life science organizations, we pride ourselves on taking uncommon scientific paths to overcoming disease. Our investigators are selected to become authorities in leading or creating new fields, and we work to provide them with resources to explore bold new thoughts, form effective scientific teams, and create or master emerging research technologies that accelerate progress—Gladstone’s special recipe for success that has yielded some of the most important biomedical advances of our time. Our three disease-focused institutes constitute the core of our discovery engine, but do not operate in isolation. We are seizing unprecedented opportunities for “convergence”—defined as the blending of intellectual and physical assets from multiple scientific disciplines and fields to speed the discovery process in our attack on unsolved health problems that affect almost every human family.
- 网站
-
https://www.gladstone.org
Gladstone Institutes的外部链接
- 所属行业
- 研究服务
- 规模
- 201-500 人
- 总部
- San Francisco，California
- 类型
- 非营利机构
- 创立
- 1979
- 领域
- Biomedical、Biology、Stem Cells、Cardiovascular、Neurodegenerative、Alzheimer's 、HIV、AIDS、Virology、data science、bioinformatics、immunology和Regenerative Medicine
地点
-
主要
获取路线
1650 Owens Street
US，California，San Francisco，94158
Gladstone Institutes员工
动态
-
Cardiovascular disease is the world’s leading cause of death. Millions of people are living with heart failure, and more than one million babies are born with congenital heart defects every year. For Benoit Bruneau, director of the Gladstone Institute of Cardiovascular Disease, the situation is deeply personal—his father is in chronic heart failure due to a heart attack, and his teenage daughter was born with a congenital heart condition. His lab is using advanced tools and strategic collaborations to improve knowledge of how a healthy heart develops, exactly what can go wrong, and the most promising paths to fix it. Read more: https://bit.ly/3CXupM6
-
-
Meet Ada Zhu, a research associate in the Alexanian Lab at Gladstone Institutes, whose passion for heart disease research is driven by personal experience. In this interview, she shares her journey into science, her research on gene regulation in cardiovascular disease, and how Gladstone’s collaborative environment supports young scientists. Plus, she offers advice for students interested in research!
-
Gladstone is currently in the midst of Open Enrollment. To kick things off, our People Services team hosted a Benefits Fair where Gladstonians were able to talk to our benefit providers and learn more about the benefits Gladstone has to offer.?? ?? #LifeatGladstone
-
-
For survivors of the most common type of stroke, called an ischemic stroke, only about five percent fully recover. Most others suffer from long-term problems, including weakness, chronic pain, or epilepsy. In a recent study, scientists at Gladstone and the regenerative medicine company SanBio have shown that a therapy derived from stem cells can restore normal patterns of brain activity after a stroke.
-
In a new study, Gladstone scientists showed that inflammation was reduced in the brain following treatment with HypoxyStat, the new compound they developed that could be useful for treating Leigh Syndrome and other mitochondrial diseases. Read more about this study from the Jain Lab ?? https://bit.ly/4gRky8e
-
-
A new study from the Jain Lab featured in ScienceAlert. Researchers at Gladstone are developing a new type of drug that mimics the physiological benefits of breathing in thin "mountain air".
-
Scientists at Gladstone developed a drug, HypoxyStat, that mimics the benefits of high-altitude oxygen levels, significantly extending the lifespan of mice with Leigh Syndrome by over three times and reversing severe symptoms. This breakthrough could offer a safe alternative to low-oxygen therapy for mitochondrial diseases and other conditions
-
Postdoc Alicer Andrew, Ph.D. shares how she balances her scientific career with other aspects of her life. Have questions for our scientists? Share them in the comments and we'll feature them in future posts! #AskaScientist